Soybean oligosaccharides strong resistance, will become the new food ingredients

Jhonggua maturity and study the impact of cultural type oligosaccharide content of soybean seeds are rich in non-digestible galactooligosaccharides (GOS). Thus, commercial mature seeds of two soybean cultivars (yellow) and two green soybean seed (not mature) should be green soybean seed from intensive farming, and should be green soybean seed biological growth. carbohydrate (low molecular weight, LMWC) as a drug carrier in the soybean seeds with 85% ethanol and determined by spectrophotometry and high performance liquid Chromatography major soybean seed cloud liquid water distribution: stachyose, raffinose and sucrose oligosaccharides showed no significant effect, by biological or intensive culture techniques contrary, but in accordance with the maturity of GOS content found soybean seeds. Soybean seeds, yellow Show Advanced oligosaccharide content (1.84 - 1.95%), compared with immature green seeds (1.43 - 1.61% Other grain content by maturity, thus making the relative percentage, immature, GOS (47 - 53% ) Mature (21 more than the soybean seed -. 34%) In addition, purify soybean GOS higher biological growth of soybean seeds yellow GOS content and methods have been reported, although it contains GOS choice been enriched, the resulting yield is low and effective purification has not been well implemented. Based on these results, yellow soybean seeds seem to be a good source, but GOS, in order to improve their purification, simple methods in medical colleges will be further development and evaluation.

Something you want to know Pharmaceutical Chemicals Syringa vulgaris

Product name:Syringa vulgaris
CAS: 118-34-3
Molecular Formula:C17H24O9
Molecular Weight: 372.3671
Product description:Bleeding, Syringa vulgaris is a kind of strong toxic liver drug resistance, with recovery microsomal enzyme system of enzyme activity and inhibition of lipid peroxidation, can promote the metabolism of liver poison, and improve liver function, make its normalization.

See here for more information:Buy Syringa vulgaris


 Syringa vulgaris, commonly known as the common lilac, erect, more stems, suckering, Bush is in a mature olive family usually 12-16 "(20 ') high, wide and 8-12 spread" (15'). It comes from the forests, rocky hills and jungle region in south-eastern Europe open, but in the whole of Europe (beginning in the late 16th century) and is widely used in North America (in the early 17th century brought colonists) cultivation. Very fragrant, tubular with its unique mid to late spring (May) bloom mentioned, 4-lobed, lilac purple flowers (including 1/3 "long), the narrowing of the large pyramidal panicles (6-8 bloom "long). Took a road cluster smooth, brown, crushed, cracked seed capsules (with a maximum of 3/4 "long), in the winter to do, if not eliminate clothing. Frost, on the contrary, pointed-ovate to heart-shaped leaves (2 -5 "long) as a dark gray-green to blue-green. No autumn colors. Bark is gray to gray-brown.

Doctors freelance can "cure"

After the medical service capacity and market demand huge gap widening, the Chinese health care system is facing a huge change in the situation. Under this change in the situation, change the health care industry is the trend, but in the end where to start priority to promote the eyes of the beholder, the wise see wisdom.
In the health insurance fund increasingly tight financial subsidies can not be a large-scale promotion of the status quo, to control medical expenses become the first choice policy, whether it is implemented for many years in a variety of drug prices bidding and suppress acts of drug prices, or the recently pushing the grading clinic , all from different angles in order to control medical costs. But the drugs to support medical system can not be truly effective to control the medical practices of doctors, will not be able to implement drug price control. The three patients still preferred in many cases, resulting in the rapid growth of medical expenses. This is the main reason is the patient's trust issues, even though a clear precondition for the top three restrictions on the policy, the business volume of the top three is still growing year by year and accounted for in the overall diagnosis times increased year by year.
Therefore, the current market on how to promote medical control expenses form some consensus, cancel drug addition, at the right time might peel outpatient pharmacy, strengthen more practice until the transition to freelance. On drug prices in question, as long as the policy really determined to drugs to support medical system will eventually be neutralized. But on the question of the freedom of practicing physicians, especially the freedom to practice can really promote quality resources in order to stimulate the sinking costs of medical control problems, the current situation is still difficult to be optimistic.
First, the existing health care system restricts freedom of practicing physicians. In the current health care system, doctors mainly from its level of income and business volume in which, while the patient see a doctor more attention titles and abilities. Therefore, even if the title is not high, but some doctors ability, business acceptance of their own is still limited to large hospitals. In reality the situation had low levels of a large hospital doctors more practice the occurrence of cold, its very popular with users in the major hospitals welcome, but more practice to place but deserted. This indicates that the current health care system more "not recognize recognize only the Temple monk." In this case, the development of more practice could only make those high titles of a few experts to play a role in a large number of junior doctors still can not get recognized by the market development of the business, let alone get them out of their own free practice.
Furthermore, the need for freedom to practice good national or at least regional medical services payment standards and norms, this allows the doctor can be determined according to the standard price. Now mainly rely on Medicare to develop a model has set pricing system, but the price is determined by this system of medical services is too low, the doctor will be restricted only to return to profit by the old product, which is returned to the current large public hospitals urgently needed get rid of the road, on the whole not only can not solve the current problem of controlling costs, but may be further aggravated. This is because the current health regulatory system is not perfect, can not effectively to monitor the behavior of medical problems.
Secondly, the freedom to practice or can not solve the problem of shortage of qualified doctors. The current shortage of qualified doctors, but every year a large number of high-quality graduate medical students are not engaged in medical work, mainly because the employment needs of large hospitals have is not strong, and the grassroots low incomes, few people are willing to go. On the one hand, the market demand is huge, patients flock to three hospitals, on the one hand, the grassroots insufficient supply of qualified doctors, patient demand can not be met. This is mainly caused by the payment system problem. Due mainly rely on grassroots consultation fee, but health care system limits the increase consultation fees, which led doctors revenue still can not get promoted, but also limits its ability to attract qualified doctors.
Finally, the pursuit of personal values ​​also limits doctors to start practicing freedom. Chinese concept of health education is the long-standing good doctor in the top three, only the poor academic performance before going to the grassroots level. Under the guidance of this concept, to the exclusion of their own doctor first to go grass roots, not to mention to the grass roots also get a decent income and respect. In such a situation, the patient did not dare to believe more grassroots doctors, patients would think the grassroots doctors are not capable people, or how the work will not three. This is generally caused by a vicious cycle, and also restricting the transformation of the health care system.

Buy amlodipine sources of supply

About Produts:
Product name:Amlodipine
CAS: 111470-99-6
Molecular Formula: C26H31ClN2O8S
Molecular Weight: 567.05
Product description:Antihypertensive drugs, are two hydrogen pyridine class calcium antagonists (calcium antagonists or slow channel blockers | | selective calcium channel blockers | | the prevention and treatment of angina pectoris medicine | | blood pressure medications), the blood vessels are strong selectivity, but diastolic coronary blood vessels and blood vessels, increase coronary blood flow, lower blood pressure.


From: http://www.chemicalspharm.com/products/Herb-Extract/Amlodipine-/

Pfizer mode being questioned

Today, well-known pharmaceutical analyst Bernard Munos questioned Pfizer rely on acquisitions to sustain growth of the business model in Forbes's column. Although repeated acquisitions greatly increase sales, but the net profit increase is limited. Pfizer, the market value of 120 billion in 2000, and now 200 billion, and McDonald's burger price growth rate almost. While shareholders get $ 95 billion in dividends, but Pfizer stock is now lower than in 1999 (of course, when there is a bubble biopharmaceuticals). He believes that patients decrease the use of innovative drugs is the main pressure of the whole industry growth, of course, are the same for all pharmaceutical companies. The key to survival is to improve the patient's unit profit, but price increases have been limited by space. He said Pfizer has talent, courage, have the resources, do not need to transfer the headquarters of such means of tax avoidance

Progress in the field of AIDS research breakthrough year 2015

Currently, there are 35 million people worldwide living with HIV, the majority of people who need AIDS drugs did not conditions for treatment. 2001 3.4 million new global HIV infections, and 2013 new cases decreased 38 percent, to 210 million; 75% of those infected are mainly concentrated in 15 countries, such as in sub-Saharan Africa, Nigeria, the number of new HIV infections in South Africa and Uganda, three countries accounted for 48% of the total.

In the past few years, the number of AIDS deaths decreased by 20%. According to the UNAIDS report, HIV in humans is expected to end in 2015 after the popular, and "The End of AIDS 2030" in. In order to achieve this desire, the world's governments, organizations will need to work together, of course, which also lack the scientists you can not continue to engage in AIDS research.

( Bolise Co., Ltd. www.chemicalspharm.com ) 

Samsung will invest $ 740 million to build a new biological laboratories

Samsung Group's new bio-pharmaceutical Friday announced that it will spend $ 740 million to build a new plant in South Korea, after the completion of pharmaceutical production capacity can be doubled. The company is expected to be completed by 2018.

Samsung Biological Products Co., Ltd. was founded in 2011, 97 percent by Samsung Electronics Holdings, the new plant is completed, Samsung is expected to become the world's largest bio-pharmaceutical companies foundry. Currently, Samsung biological already operates a production plant, next year will build a second plant is five times as large former, and now plans to build a third annual capacity of 180,000 liters goals. New plant construction plan highlights the Samsung ambition Pharmaceutical Technology in.

Analysts said, as the slowdown in the smart phone business, Pharmaceutical Technology described under the Samsung Group has a business growth potential. Samsung said it wanted to succeed semiconductor manufacturing operations into the production of biological science and technology among.